<DOC>
	<DOCNO>NCT00702403</DOCNO>
	<brief_summary>This phase I/II trial study side effect best way give nilotinib give together imatinib mesylate donor stem cell transplant treat patient acute lymphoblastic leukemia chronic myelogenous leukemia . Nilotinib imatinib mesylate may stop growth cancer cell block enzymes need cell growth .</brief_summary>
	<brief_title>Nilotinib Imatinib Mesylate After Donor Stem Cell Transplant Treating Patients With Acute Lymphoblastic Leukemia Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine safety administration nilotinib Day 81 Day 365 hematopoietic cell transplantation ( HCT ) patient Philadelphia chromosome positive ( Ph+ ) leukemia . SECONDARY OBJECTIVES : I . To quantify breakpoint cluster region ( BCR ) /Abelson murine leukemia ( ABL ) transcript load HCT tyrosine kinase inhibitor therapy patient Ph+ leukemia treat sequentially imatinib ( imatinib mesylate ) nilotinib time engraftment . II . To evaluate survival 1 year patient Ph+ leukemia receive sequential imatinib nilotinib time engraftment . III . To determine imatinib co-administered nilotinib patient rise level BCR/ABL 2 consecutive occasion HCT . IV . To confirm imatinib deliver average daily dose 400 mg least 85 % time majority adult first 80 day HCT . V. To determine whether nilotinib administer safely daily dose least 300 mg ( 175 mg/m^2 child &lt; 17 year ) least 70 % time patient imatinib resistant Ph+ leukemia first 80 day HCT . VI . To determine treatment efficacy success 1 year post-transplant demonstrate complete hematological remission , absence Philadelphia chromosome , satisfy criterion treatment failure . OUTLINE : Beginning engraftment blood count recover ( 21-28 day allogeneic stem cell transplant ) , patient imatinib-sensitive leukemia receive imatinib mesylate orally ( PO ) daily ( QD ) day 80 nilotinib PO twice daily ( BID ) day 81-445 . Patients imatinib-resistant leukemia receive nilotinib PO BID begin engraftment blood count recover day 445 . Treatment continue absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Leukemia , Myeloid , Accelerated Phase</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Body surface area &gt; = 1 m^2 Allogeneic HCT Acute lymphocytic leukemia ( ALL ) chronic myelogenous leukemia ( CML ) characterize p190 and/or p210 BCR/ABL gene rearrangement CML accelerate phase , blast crisis , blast crisis remission define World Health Organization ( WHO ) criteria CML chronic phase patient age = &lt; 17 year patient age CML second chronic phase beyond Patients minimal residual disease ( MRD ) decline response tyrosine kinase inhibitor therapy must screen T315I mutation An appropriately match relate unrelated donor Signed informed consent Patient must life expectancy least 2 month Stated willingness patient comply study procedure report requirement Creatinine = &lt; 2.0 x upper limit normal ( ULN ) Platelets &gt; 20 x 10^9 /L Serum aspartate aminotransferase ( AST ) /alanine aminotransferase ( ALT ) = &lt; 3 x ULN , conjugate bilirubin &lt; 3 x ULN Serum potassium phosphorus , magnesium , calcium &gt; = low limit normal ( LLN ) correctable supplement prior first dose study drug ; calcium level may correct hypoalbuminemia Serum amylase lipase &lt; 1.5 x ULN Female patient childbearing potential must negative pregnancy test within 7 day initiation study drug dosing ; postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential ; male female patient reproductive potential must agree employ effective barrier method birth control throughout study 3 month follow discontinuation study drug Careful rationalization view discontinue consider alternative concomitant medication potential prolong QT interval Autologous transplant Nonmyeloablative transplant Patient age &gt; 17 year CML first chronic phase Aberrant antigen expression marrow leukemic blast &gt; = 5 % multidimensional flow cytometric assay immediately condition ( CML patient chronic phase exempt flow cytometry screen ) Ph+ ALL without complete cytogenetic remission immediately condition Known T315I mutation Hypersensitivity Gleevec Tasigna Patients Tasignaresistant intolerant Central nervous system ( CNS ) involvement leukemia baseline ( preimatinib therapy ) ; CML chronic phase ( CP ) , accelerate phase ( AP ) patient exempt CNS involvement screen Female patient pregnant , breastfeeding , childbearing potential without negative serum pregnancy test screening ; male female patient childbearing potential unwilling use effective contraceptive precaution throughout trial ; postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential Life expectancy severely limited disease leukemia Myocardial infarction within one year prior start nilotinib Other clinically significant heart disease ( e.g . congestive heart failure , uncontrolled hypertension , unstable angina ) Absolute neutrophil count ( ANC ) less 1500 per microliter study entry despite use filgrastim ( GCSF ) Impaired cardiac function , include one following : Complete leave bundle branch block bifascicular block ( right bundle branch block plus leave anterior hemiblock ) use ventricularpaced pacemaker Congenital long QT syndrome family history long QT syndrome History presence significant ventricular atrial tachyarrhythmias Clinically significant rest bradycardia ( &lt; 50 beat per minute ) QTc &gt; 450 millisecond screen electrocardiogram ( ECG ) ; QTc &gt; 450 electrolyte within normal range , electrolyte correct patient rescreened QTc</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>